Covid-19: a treatment authorized in the hope that it will be effective against Omicron

Aimed at those over the age of 12 at risk, the treatment is currently the only authorized treatment for people infected with Omicron.

A new anti-Covid treatment with synthetic antibodies, Xevudy, has been approved by the French health authorities, who consider it promising against infection by Omicron while other drugs have just been withdrawn because of their ineffectiveness against the new variant. Read alsoCovid-19: this treatment that remains effective against Omicron Based on the sotrovimab molecule, it will therefore be, for the time being, the only antibody treatment that can be used after a proven infection with Omicron. Another treatment of this type, Evusheld from AstraZeneca, is also considered effective against Omicron but it is given preventively, especially in people whose body is resistant to vaccination. SEE ALSO – Antivirals, corticosteroids… Dr Benjamin Rossi provides an update on treatments for serious forms Covid-19

Administration by intravenous The High Authority for Health (HAS) “ authorizes early access to a new curative treatment, Xevudy (…) of GSK ”, announced this body in a press release. This medicine is intended for people over the age of 12 who have just been infected with the coronavirus and are considered at risk of a severe form. “It is recommended to administer it within five days of the onset of symptoms”, explains the authority. Xevudy is administered intravenously. It is part of the synthetic antibody treatments, several of which have already been authorized since the start of the pandemic. But the arrival of the Omicron variant, which is more resistant to vaccines and other drugs, has made some of these treatments obsolete. The French health authorities thus ceased at the beginning of January to recommend Ronapreve from Roche in the event of infection with Omicron, even if it remains authorized against Delta, the previous dominant variant. Worse, they completely withdrew Eli Lilly’s bamlanivimab/etesivimab combination from circulation, its results also showing disappointment against Delta. Contrary to these two treatments, Xevudy «has a mechanism of action which makes it possible to hope for the maintenance of its effectiveness on the variants , including the Omicron variant”, explains the HAS. “ In vitro data suggest maintenance of the neutralizing activity of sotrovimab when that of the other available monoclonal antibodies decreases or even disappears”, she explains.

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Arbitrum (ARB) Surge Anticipated: Analysts Eye Macro Targets between $5.75-$9 thumbnail

Arbitrum (ARB) Surge Anticipated: Analysts Eye Macro Targets between $5.75-$9

You are here: Home / News / Arbitrum (ARB) Surge Anticipated: Analysts Eye Macro Targets between $5.75-$9 Arbitrum (ARB) is currently attracting attention as it positions itself for notable upward movements. Presently, the price of ARB stands at $1.062961, accompanied by a 24-hour trading volume of $401.20 million and a market capitalization of $2.82 billion. Over the
Read More
Bug Hunter Gets $2.1 Million for Discovering Optimism Flaw thumbnail

Bug Hunter Gets $2.1 Million for Discovering Optimism Flaw

By Mark Hunter5 days agoTue Feb 15 2022 13:52:42 Reading Time: 2 minutesA “gray hat” hacker has described how he identified a critical Ethereum bug The bug, in the Optimism L2 code, could have allowed limitless minting of ETH Jay Freeman picked up $2.1 million in bug bounties for the find A “gray hat” hacker…
Read More
Blockchain-Based Supply Chain Management in 2023 thumbnail

Blockchain-Based Supply Chain Management in 2023

Supply chain management is a critical component of businesses in a variety of industries, ranging from manufacturing to retail. However, managing a complex supply chain can be difficult because of issues with transparency, traceability, and efficiency. Enter blockchain technology, which has the potential to transform supply chain management by providing an immutable and transparent ledger
Read More
3 Ways Hospitals Can Boost Worker Engagement thumbnail

3 Ways Hospitals Can Boost Worker Engagement

An analysis of six years of data from more than 80 hospitals and more than 192,000 employees in Victoria, Australia, adds to the evidence that employee engagement in their jobs matters. It found that happier workers improved hospital performance in terms of hospital costs, treatment effectiveness, and hospital-acquired infections and conditions. In particular, the research identifies…
Read More
New high return debt products: Should you invest? thumbnail

New high return debt products: Should you invest?

Since the past four to five years, fixed income investors have been a miserable lot as they have been hit hard by extremely low interest rates over the past. However, this period has also seen the emergence of new-age digital platforms for alternative investments which allow investors earn double digit returns. "For individual investors traditionally…
Read More
FCA Warns Social  Platforms Over Fraudulent Crypto Ads thumbnail

FCA Warns Social Platforms Over Fraudulent Crypto Ads

The UK’s financial services watchdog, the Financial Conduct Authority (FCA) will work with platforms to eliminate ads for risky financial products. During the FCA’s annual meeting on Sept. 28, the watchdog group said that they are cracking down on dangerous ads. Specifically, those that have to do with financial services such as cryptocurrency. The FCA…
Read More
Index Of News
Total
0
Share